手法を比較

	掻痒視覚アナログ尺度（掻痒VAS）	POEM（患者中心型湿疹重症度評価尺度）	SCORAD指数（アトピー性皮膚炎スコアリング）
分野	皮膚科学	皮膚科学	皮膚科学
系統	Process / pipeline	Process / pipeline	Process / pipeline
提唱年	1983 (VAS); widely adopted for pruritus 1990s–2000s	2004	1993
提唱者	Huskisson EC (VAS methodology); adapted for pruritus in dermatology	Charman CR, Venn AJ, Williams HC	European Task Force on Atopic Dermatitis (ETFAD)
種類	Self-report	Self-report	Clinician-rated
原典	Elman S, Hynan LS, Gabriel V, Mayo MJ. The 5-D itch scale: a new measure of pruritus. Br J Dermatol. 2010;162(3):587-593.	Charman CR, Venn AJ, Williams HC. The Patient-Oriented Eczema Measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol. 2004;140(12):1513-1519.	Kunz B, Oranje AP, Labrèze L, et al. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1997;195(1):10-19.
別名	Itch VAS, Pruritus Severity Scale	POEM Score	SCORAD Index
関連	3	2	3
概要	The Pruritus Visual Analog Scale (VAS) is a simple, single-item patient-administered tool measuring itch intensity on a continuous 0–10 (or 0–100) scale. Adapted from the original VAS for pain, it is one of the most frequently used outcome measures in dermatological research and clinical practice due to its simplicity, brevity, and responsiveness to treatment. Pruritus VAS is essential in trials of antipruritic therapies and in conditions where itching is a primary complaint (atopic dermatitis, psoriasis, pruritus ani, lichen planus).	The POEM is a brief, patient-administered severity measure for atopic dermatitis that focuses on frequency of symptoms experienced over the past week. Developed by Charman, Venn, and Williams in 2004, it emphasizes the patient's lived experience rather than clinician observation, making it practical for routine clinical practice and remote monitoring. POEM is increasingly used alongside objective measures in clinical trials and outpatient care.	The SCORAD is a comprehensive clinician-administered tool for measuring the extent and severity of atopic dermatitis (eczema). Developed by the European Task Force on Atopic Dermatitis in 1993, it combines objective clinical assessment with subjective symptom reporting. It is the gold standard for atopic dermatitis severity in clinical trials and dermatology practice.